Search
Palvella Therapeutics Inc
PVLAAdd to Watchlist
146.760USD
+8.500+6.15%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.63BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+6.15%
5 Days
-0.98%
1 Month
+27.82%
6 Months
+46.35%
Year to Date
+40.21%
1 Year
+508.46%
Key Figures
138.580Open
146.880High
321.86KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.90%Turnover Ratio
138.260Prev. Close
136.770Low
31.00MTurnover
LossP/E Static
42.07P/B
0.00%Div Yield TTM
-28.73%ROA
151.18052wk High
0.99Volume Ratio
-17.43MNet Profit
11.09MShares
-4.1694EPS TTM
-0.14Beta
-34.25%ROE
20.20052wk Low
7.31%Amplitude
100.00%Gross Margin
1.63BMarket Cap
4.65Reward/Risk
4.39%Risk Rate
TradingKey Stock Score of Palvella Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Palvella Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 229.00.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Palvella Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Palvella Therapeutics Inc Highlights
StrengthsRisks
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -35.20, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 11.89M shares, increasing 11.46% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 33.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.76.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
229.000
Target Price
+65.63%
Upside Space
Palvella Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Palvella Therapeutics Inc Info
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Ticker SymbolPVLA
CompanyPalvella Therapeutics Inc
CEOKaupinen (Wesley H)
Websitehttps://palvellatx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Palvella Therapeutics Inc (PVLA)?
The current price of Palvella Therapeutics Inc (PVLA) is 146.76.
What is the symbol of Palvella Therapeutics Inc?
The ticker symbol of Palvella Therapeutics Inc is PVLA.
What is the 52-week high of Palvella Therapeutics Inc?
The 52-week high of Palvella Therapeutics Inc is 151.18.
What is the 52-week low of Palvella Therapeutics Inc?
The 52-week low of Palvella Therapeutics Inc is 20.20.
What is the market capitalization of Palvella Therapeutics Inc?
The market capitalization of Palvella Therapeutics Inc is 1.63B.
Is Palvella Therapeutics Inc (PVLA) currently rated as Buy, Hold, or Sell?
According to analysts, Palvella Therapeutics Inc (PVLA) has an overall rating of Buy, with a price target of 229.00.
What is the Earnings Per Share (EPS TTM) of Palvella Therapeutics Inc (PVLA)?
The Earnings Per Share (EPS TTM) of Palvella Therapeutics Inc (PVLA) is -3.71.